Labcorp Holdings Inc (LH) FinancialsLHLabcorp Holdings Inc

Labcorp Holdings Inc. (LH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is DX, accounting for 78.1% of total sales, equivalent to $2.76B. Other significant revenue streams include BLS and Intercompany eliminations. Understanding this composition is critical for investors evaluating how LH navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Labcorp Holdings Inc. maintains a gross margin of 27.71%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 12.24%, while the net margin is 8.02%. These profitability ratios, combined with a Return on Equity (ROE) of 11.74%, provide a clear picture of how effectively LH converts its operational activities into shareholder value.

In the context of the broader market, LH competes directly with industry leaders such as PHG and SOLV. With a market capitalization of $25.80B, it holds a significant position in the sector. When comparing efficiency, LH's gross margin of 27.71% stands against PHG's 49.31% and SOLV's 58.62%. Such benchmarking helps identify whether Labcorp Holdings Inc. is trading at a premium or discount relative to its financial performance.

Labcorp has demonstrated solid financial performance with a total revenue increase of 6.4% year-over-year, and net income reaching $1 billion. The gross margin has improved to 27.71%, reflecting effective cost management and operational efficiency.